Immix Biopharma, Inc. — Q3 2023 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three and nine months ended September 30, 2023. Immix is a clinical-stage biopharmaceutical company with no product revenue to date. Its programs include NXC-201 CAR-T, in Phase 1b/2a trials for relapsed or refractory AL amyloidosis and multiple myeloma, and IMX-110, being developed for solid tumors.
Financial results and liquidity
| Metric | Three months ended Sept. 30, 2023 | Nine months ended Sept. 30, 2023 | Prior-year comparison |
|---|---|---|---|
| Revenue | None reported | None reported | None reported |
| Operating expenses | $4.52 million | $10.77 million | $1.53 million and $4.42 million, respectively |
| Research and development | $2.11 million | $5.63 million | $0.70 million and $1.93 million, respectively |
| General and administrative | $2.42 million | $5.13 million | $0.84 million and $2.49 million, respectively |
| Net loss | $4.34 million | $10.44 million | $1.54 million and $4.43 million, respectively |
| Loss per share, basic and diluted | $0.23 | $0.65 | $0.11 and $0.32, respectively |
- At September 30, cash and cash equivalents were $19.58 million; working capital was approximately $19.5 million. Total assets were $22.47 million and total liabilities were $2.83 million, all current. The filing reports no outstanding debt on the balance sheet.
- For the first nine months, operating cash outflow was $8.69 million, investing cash outflow was $0.04 million, and financing cash inflow was $14.88 million. Cash increased by $6.15 million from year-end 2022.
- Interest income was $0.34 million for the nine months, versus none in 2022. The company reported no gross profit or operating margin because it had no revenue.
Material changes and financing
- Year-over-year operating expenses and net loss increased, primarily with higher clinical-trial and CRO costs, professional services, investor relations spending, compensation, and stock-based compensation.
- In 2023, Immix raised net proceeds of approximately $4.81 million through its March ATM, $0.19 million through its July ATM by September 30, and $9.93 million in an August private placement. The placement included 3.24 million common shares and pre-funded warrants for 1.91 million additional shares.
- Shares issued increased from 13.96 million at December 31, 2022, to 19.68 million at September 30, 2023. After quarter-end, additional ATM sales were reported; the filing gives different post-period share/proceeds figures in different sections, so investors should check the latest company disclosure.
Outlook, risks, and unusual items
- Management estimates cash on hand and potential July ATM proceeds will fund planned operations through at least November 9, 2024. The company expects continuing losses and negative operating cash flow, and states it will need additional financing; no credit facility or committed capital source is in place. Further equity financing could dilute shareholders.
- Nexcella’s HADASIT/BIRAD license entails approximately $13 million in additional quarterly clinical-trial support payments through September 2026, a $50,000 annual license fee, royalties of 5% of net sales, and sales milestones of up to $20 million. These are future contractual commitments, not current-period expenses in their entirety.
- The company reported a material weakness in internal control over financial reporting, citing limited personnel and insufficient formal accounting review procedures. Disclosure controls were deemed ineffective; management said it was adding accounting consultants and working on remediation.
- Key risks include clinical and regulatory uncertainty, dependence on third-party trial providers and manufacturers, need for future capital, possible dilution and resale overhang from outstanding shares and warrants, and uncertainty about access to capital. The filing reports no material pending litigation.
- The filing identifies no specific financial guidance beyond the stated cash runway estimate. Clinical results, trial timing, regulatory outcomes, and eventual commercialization remain uncertain.
Important facts for investors to verify
- Current cash runway, actual spending pace, and remaining capacity under the July ATM facility.
- Latest post-quarter ATM proceeds and share issuances, given differing post-period figures in the filing.
- Clinical-trial progress, costs, and results for NXC-201 and other development programs.
- Potential dilution from the pre-funded warrants, options, ATM issuance, and registered resale shares.
- Progress remediating the material weakness and whether disclosure controls become effective.
- Ability to meet Nexcella license and clinical-trial commitments while securing additional funding.